Struggles for equivalence: in vitro developmental toxicity model evolution in pharmaceuticals in 2006

Area of Science:

• Developmental toxicology
• Stem cell assays
• Pharmacology

Background:

• The Embryonic Stem Cell (ESC) assay is utilized for predicting developmental toxicity.
• Existing methods using gene expression and statistical analysis have not sufficiently improved the discrimination between weak teratogens and non-teratogens.
• A low cytotoxicity IC50 value can inappropriately influence test results for pharmaceuticals.

Purpose of the Study:

• To enhance the discrimination of weak teratogens from non-teratogens in developmental toxicity testing.
• To re-evaluate and improve the cytotoxicity component of the ESC assay.
• To develop a more accurate method for identifying weak teratogens and non-teratogens.

Main Methods:

• Employing measures of gene expression alongside the ECVAM Embryonic Stem Cell assay.
• Utilizing alternative statistical methods for data analysis.
• Investigating novel and more sensitive cytotoxicity measures.
• Analyzing gene expression changes in mouse stem cells.

Main Results:

• Previous attempts to improve discrimination using gene expression and modified statistical methods were unsuccessful.
• A key finding is the inappropriate influence of low cytotoxicity IC50 values on test outcomes.
• Current efforts focus on integrating refined cytotoxicity measures with gene expression data.

Conclusions:

• The current Embryonic Stem Cell assay requires refinement, particularly in its cytotoxicity assessment, to accurately predict developmental toxicity.
• Improved cytotoxicity measures combined with gene expression analysis in mouse stem cells are crucial for correctly identifying weak teratogens and non-teratogens.
• Further research is needed to optimize these approaches for pharmaceutical safety assessment.